Publications by authors named "K H Nocka"
Vitiligo is a common chronic autoimmune disease characterized by white macules and patches of the skin, having a negative impact on patients' life and without any definitive cure at present. Identification of new compounds to reverse depigmentation is therefore a pressing need for this disease. The pharmacologic compounds phosphodiesterase-4 inhibitors (PDE4is) are small molecules with immunomodulatory properties used for treatment of inflammatory dermatoses.
View Article and Find Full Text PDFBackground: Safe and effective long-term topical treatments for atopic dermatitis (AD) remain limited.
Objective: In this phase 2a, single-center, intrapatient, and vehicle-controlled study, we examine the mechanism of action of crisaborole 2% ointment, a topical nonsteroidal PDE4 (phosphodiesterase-4) inhibitor, in a proteomic analysis of 40 adults with mild to moderate AD and 20 healthy subjects.
Methods: Within the AD cohort, 2 target lesions were randomized in an intrapatient (1:1) manner to double-blind crisaborole/vehicle applied twice daily for 14 days.
Article Synopsis
- Interleukin (IL)25 plays a key role in causing inflammation and maintaining tissue health at barrier surfaces in various organs, prompting the need to develop a neutralizing antibody targeting it.
- Researchers created a novel antibody called 22C7, which effectively inhibits IL25's inflammatory effects in mouse models, including significant reductions in immune cell recruitment and skin inflammation.
- The findings support 22C7 as a promising therapeutic option for treating conditions related to IL25, with further engineering aimed at making it a fully human antibody while preserving its effectiveness.
Background: Concerns about the actual and perceived costs of pre-exposure prophylaxis (PrEP) continue to be a major barrier to uptake among gay, bisexual and men who have sex with men (GBMSM) in the United States.
Methods: We conducted semi-structured interviews with 25 GBMSM who presented for routine health care at a STD clinic in the northeastern United States. The cohort included GBMSM who were or were not currently taking PrEP and represented varied health care coverage and financial resources.
Background: Since COVID-19 first appeared in the United States (US) in January 2020, US states have pursued a wide range of policies to mitigate the spread of the virus and its economic ramifications. Without unified federal guidance, states have been the front lines of the policy response.
Main Text: We created the COVID-19 US State Policy (CUSP) database ( https://statepolicies.